Kiora Pharmaceuticals Inc (KPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) has a cash flow conversion efficiency ratio of -0.112x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.89 Million) by net assets ($16.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kiora Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Kiora Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kiora Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kiora Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiora Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Kiora Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Condor Energy Ltd
AU:CND
|
-0.099x |
|
Tartisan Nickel Corp
F:8TA
|
-0.055x |
|
Dynaciate Group Bhd
KLSE:5178
|
0.016x |
|
Profithol S.A.
MC:SPH
|
-0.745x |
|
Commcenter S.A.
MC:CMM
|
0.286x |
|
Libet S.A.
WAR:LBT
|
-0.036x |
|
Shyam Century Ferrous Limited
NSE:SHYAMCENT
|
-0.476x |
|
Lion Metal Works Tbk
JK:LION
|
0.029x |
Annual Cash Flow Conversion Efficiency for Kiora Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kiora Pharmaceuticals Inc from 2012 to 2025. View KPRX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.13 Million | $-9.96 Million | -0.618x | -285.90% |
| 2024-12-31 | $25.76 Million | $8.56 Million | 0.332x | +121.24% |
| 2023-12-31 | $6.11 Million | $-9.56 Million | -1.564x | -71.12% |
| 2022-12-31 | $11.41 Million | $-10.43 Million | -0.914x | -24.84% |
| 2021-12-31 | $14.58 Million | $-10.68 Million | -0.732x | +2.63% |
| 2020-12-31 | $9.73 Million | $-7.32 Million | -0.752x | +38.92% |
| 2019-12-31 | $6.62 Million | $-8.15 Million | -1.231x | -1.46% |
| 2018-12-31 | $8.94 Million | $-10.84 Million | -1.214x | -136.15% |
| 2017-12-31 | $-1.93 Million | $-6.47 Million | 3.357x | -86.86% |
| 2016-12-31 | $-329.42K | $-8.41 Million | 25.539x | +3586.11% |
| 2015-12-31 | $6.09 Million | $-4.46 Million | -0.733x | -3184.65% |
| 2014-12-31 | $-40.03 Million | $-950.62K | 0.024x | -69.25% |
| 2013-12-31 | $-38.29 Million | $-2.96 Million | 0.077x | -48.50% |
| 2012-12-31 | $-34.81 Million | $-5.22 Million | 0.150x | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more